Since this may be managed by the editorial office, I do not see the need for another review.
When explaining the choice of regional cases, the term ‘representative’ appears misleading. It seems that the most prominent or successful cases have been selected, at least for Germany and France. How can these be ‘representative’ for whatever population of biotech clusters in these countries?